Boston Scientific‘s Precision Spectra spinal cord stimulator (SCS) system is claimed to provide one and a half times better overall pain relief and two times better low back pain relief than the previous generation PRECISION PLUS SCS system in a recent study.
A part of the company’s PRO observational study, the Lumina cohort study consisted of three patient groups, the first of which included 213 consecutive patients who were treated with the Precision Spectra system for up to 24 months post-implant.
The second group included 130 consecutive patients who were treated with Precision Plus, in a comparative evaluation with the Precision Spectra system, while the third featured 25 patients treated with the system and the new CoverEdge 32 surgical leads for up to six months post-implant.
In the Lumina Spectra group, the system lowered overall pain from an average baseline score of 7.17 to 2.98 at 24 months post-implant. Patients with only low back pain in the same group reported a sustained and significant reduction from an average baseline score of 7.21 to 3.2.
The improvement with Spectra was more than twice that of its predecessor for low back pain.
In the Lumina surgical group, the six months post-implant group observed significant reduction in overall pain from an average baseline score of 7.7 to 2.7.
One of the lead investigators for the study Julie Pilitsis said: "This is strong clinical evidence of the effectiveness of the Precision Spectra system in treating the types of challenging chronic pain patients that physicians see every day."
Claimed to be the first and only SCS system with Illumina 3D software and 32 contacts, Precision Spectra SCS is capable of providing improved pain relief to patients suffering from chronic pain.
Due to the presence of more contacts, the system also provides more coverage of the spinal cord for management of chronic pain.
The Precision Plus SCS system provides a maximum of 16 contacts and two lead ports, with each lead port facilitating the placement of a single lead.